Industry Roundtable (Part 2)

SEEKING FEEDBACK TO HELP US ADVANCE DIVERSITY IN DERMATOLOGY FASTER

Rhonda Peebles is Vice-President & Head of US Dermatology at UCB Pharmaceuticals, where she leads the cross-functional commercial, sales, and marketing teams to establish a leadership position for UCB in the dermatology marketplace for existing and future brands. With over 20 years of experience in healthcare, she possesses dynamic and results-oriented sales and marketing expertise, including product launches, global strategic planning, and customer relationship management. She is passionate about uncovering solutions that help healthcare providers and their patients. She holds a BS in Environmental Health Science from Eastern Kentucky University and an MS in Toxicology from the University of Kentucky. She completed the Executive Education Course in Finance & Accounting at the Wharton School of Business for Executives, University of Pennsylvania. Rhonda resides in Atlanta, GA, with her beloved dog, Jake, and is originally from Louisville, KY.

DIVERSITY IN DERMATOLOGY CLINICAL TRIALS - ENGAGING PATIENTS & HCPS, BUILDING TRUST

Paul J. Rowe, MD, ATSF has well over a decade of research experience spanning from pre-clinical to late phase innovative medical therapy development programs, primarily in respiratory (and cardiovascular) medicine within the pharma industry. He has been directly responsible for medical strategy and lifecycle management of several Chronic Obstructive Pulmonary Disease (COPD), asthma, thrombosis, and cardiovascular medicines. Dr. Rowe is an active member of several national and international societies. He recently served as Vice Chair of the Drug, Device, Discovery, and Development Committee of the American Thoracic Society (ATS) and has received the distinction of being named a Fellow of the society. He is primarily interested in promoting international medical research collaboration and innovation across government, academia, and industry. In his current role, Dr. Rowe is responsible for building and leading a Global Medical team and strategy within the Immunology space for novel compounds in mid and late stage development in various therapeutic disease state indications.

DISRUPTING INCLUSIVITY IN THE BEAUTY INDUSTRY

Janet Wangari-Olivero, PhD serves as a Director in L’Oréal Research and Innovation having joined the company in 2015. In her role, she provides leadership and direction in basic and clinical research focused on skin, scalp, and hair loss. She also leads a multidisciplinary task force dedicated to ensuring that the research, as well as models and methods, meet the ever-evolving diversity and inclusivity needs. Previously, she oversaw various clinical trials covering multiple aspects of dermatology such as treatment of pigmentary disorders and photoprotection in Skin of Color. Dr. Wangari-Olivero received her PhD in cell and developmental biology from Rutgers University and completed two postdoctoral fellowships at Fox Chase Cancer Center and Johnson & Johnson Consumer Health.

GALDERMA: ADVANCING EVERY SKIN STORY

JP York, PhD is Associate Director of Medical Affairs at Galderma Laboratories, based out of Fort Worth, Texas. He earned his Ph.D. in Molecular Physiology and Biophysics from Baylor College of Medicine, where he studied cell cycle genes in embryonic development. His post-doctoral studies were conducted at the Houston Methodist Research Institute on the role of nuclear receptors in cholangiocarcinoma. His primary focus at Galderma has been advancing the science of Acne and Rosacea.

REVISION SKINCARE’S CLINICAL STRATEGY ON DIVERSITY: PAST, PRESENT, AND FUTURE

Alisar S. Zahr, PhD is the Director of Research and Clinical Development at Revision Skincare®. As head of the department, her responsibilities include researching novel ingredients and technology for incorporation into Revision’s new product pipeline, conducting, analyzing, and publishing clinical studies to further cement Revision Skincare’s science. Dr. Zahr is considered a subject matter expert in the formulation of sunscreens and anti-aging treatments. Throughout her career in the personal cosmetics industry, she has formulated and successfully brought products to the market, such as Neutrogena, Roc, Clean & Clear, Aveeno, and eltaMD. As evident from Dr. Zahr’s prior work experience, she is passionate about engineering solutions for unmet needs in dermatology. She is focused on creating products that improve patients’ long-term skin health.